Adherence to insulin treatment in insulin-naïve type 2 diabetic patients initiated on different insulin regimens

Patient Preference and Adherence

Volumn 9, Issue , 2007, Pages 1225-1231

  Yavuz, Dilek Gogas ^a   Ozcan, Sevim ^a   Deyneli, Oguzhan ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Basal bolus insulin regimen; Insulin treatment adherence; Premixed insulin regimen; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PATIENT ATTITUDE; PATIENT COMPLIANCE; QUESTIONNAIRE; SELF REPORT; TELEPHONE INTERVIEW; TREATMENT DURATION;

EID: 84940053903     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S87935     Document Type: Article

References (39)

1. Sorli C, Heile MK. Identifying and meeting the challenges of insulin therapy in type 2 diabetes. J Multidiscip Healthc. 2014;7:267–282.
2. Peyrot M, Rubin RR. Perceived medication benefits and their association with interest in using inhaled insulin in type 2 diabetes: a model of patients’ cognitive framework. Patient Prefer Adherence. 2011;5:255–265.
3. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825–834.
4. Buysman E, Conner C, Aagren M, Bouchard J, Liu F. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes. Curr Med Res Opin. 2011;27(9):1709–1717.
5. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–1224.
6. Cheen HH, Lim SH, Huang MC, Bee YM, Wee HL. Adherence to premixed insulin in a prefilled pen compared with a vial/syringe in people with diabetes in Singapore. Clin Ther. 2014;36(7):1043–1053.
7. Del Prato S, Penno G, Miccoli R. Changing the treatment paradigm for type 2 diabetes. Diabetes Care. 2009;32 Suppl 2:S217–S222.
8. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682–689.
9. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW; DARTS/MEMO Collaboration. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet. 1997;350(9090):1505–1510.
10. Aronson R. The role of comfort and discomfort in insulin therapy. Diabetes Technol Ther. 2012;14(8):741–747.
11. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25(2):330–336.
12. pharmafile. com [homepage on the Internet]. Treatment flexibility will improve adherence in diabetes, study suggests. Samedan Ltd; 2011. Available from: http://www.pharmafile.com/news/161079/treatment-flexibility-will-improve-adherence-diabetes-study-suggests. Accessed July 2, 2015.
13. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3–12.
14. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab. 2012;14:1081–1087.
15. Spann SJ, Nutting PA, Galliher JM, et al. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med. 2006;4(1):23–31.
16. Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33(4):733–735.
17. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240–245.
18. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001;23(8):1311–1320.
19. Bonafede MM, Kalsekar A, Pawaskar M, et al. A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures. Patient Prefer Adherence. 2010;4:147–156.
20. Knecht LA, Gauthier SM, Castro JC, et al. Diabetes care in the hospital: is there clinical inertia? J Hosp Med. 2006;1(3):151–160.
21. Schnipper JL, Barsky EE, Shaykevich S, Fitzmaurice G, Pendergrass ML. Inpatient management of diabetes and hyperglycemia among general medicine patients at a large teaching hospital. J Hosp Med. 2006;1(3):145–150.
22. Ratner R, Wynne A, Nakhle S, Brusco O, Vlajnic A, Rendell M. Influence of preprandial vs postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096). Diabetes Obes Metab. 2011;13(12):1142–1148.
23. Vinagre I, Sánchez-Hernández J, Sánchez-Quesada JL, María MÁ, de Leiva A, Pérez A. Switching to basal-bolus insulin therapy is effective and safe in long-term type 2 diabetes patients inadequately controlled with other insulin regimens. Endocrinol Nutr. 2013;60(5):249–253.
24. Fritsche A, Larbig M, Owens D, Häring HU; GINGER study group. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab. 2010;12(2):115–123.
25. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B; PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab. 2009;11(1):45–52.
26. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008;31(1):20–25.
27. Oliveria SA, Menditto LA, Ulcickas Yood M, Koo YH, Wells KE, McCarthy BD. Barriers to the initiation of, and persistence with, insulin therapy. Curr Med Res Opin. 2007;23(12):3105–3112.
28. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33(6):1014–1029; discussion 1030–1031.
29. Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836–2848.
30. Flood T. Advances in insulin delivery systems and devices: beyond the vial and syringe. Insulin. 2006;1(3):99–108.
31. Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in Type 2 diabetes: family physicians’ misconception of patients’ fears contributes to existing barriers. J Diabetes Complications. 2007;21(4):220–226.
32. Polonsky WH, Hajos TR, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin. 2011;27(6):1169–1174.
33. Hayes RP, Fitzgerald JT, Jacober SJ. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract. 2008;62(6):860–868.
34. Benroubi M. Fear, guilt feelings and misconceptions: barriers to effective insulin treatment in type 2 diabetes. Diabetes Res Clin Pract. 2011;93 Suppl 1:S97–S99.
35. Petznick AM. Identifying and addressing barriers to insulin acceptance and adherence in patients with type 2 diabetes mellitus. J Am Osteopath Assoc. 2013;113(4 Suppl 2):S6–S16.
36. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–2012.
37. American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care. 2014;37 Suppl 1:S14–S80.
38. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559.
39. LaSalle JR. Empowering patients during insulin initiation: a real-world approach. J Am Osteopath Assoc. 2010;110(2):69–78.